Jefferson University Hospitals

Interstitial Lung Disease

Related Content
  • Jefferson Pulmonary Associates Receives Highest Recognition
    Jefferson Pulmonary Associates Receives Highest Recognition

    Jefferson Pulmonary Associates achieves Level 3 status as a Patient-Centered Specialty Practice (PCSP) from the National Center for Quality Assurance (NCQA).


    Learn More >

Interstitial lung disease (ILD) is a term used to describe a group of conditions that cause scarring (pulmonary fibrosis) and/or inflammation in space between the air sacs of the distal lung. In most patients, inflammation and scarring gradually interfere with gas-exchange and cause slowly progressive shortness of breath, chronic dry hacking cough and decreased blood oxygen levels. The most common form of this disease is idiopathic pulmonary fibrosis.

Why Choose Jefferson for Interstitial Lung Disease Treatment?

Management of patients with interstitial lung diseases is often complex and varies depending on the underlying cause. At Jefferson, our goal is to provide patients with a multidisciplinary approach so we may expertly manage every aspect of their complex disease.  For patients referred to Jefferson, our pulmonologists work closely with a wide range of specialists including thoracic surgeons, rheumatologists, radiologists, pathologists, nurses and respiratory therapists.

At the Interstitial Lung Disease Clinic, we maintain an open line of communication between the patient and doctors at all times to ensure that all specialists on the team agree with not only the diagnosis but also the treatment plan.

The first step for patients referred to our clinic is to undergo a comprehensive evaluation to determine the cause and the best course of treatment of interstitial lung disease.

Types of Interstitial Lung Disease

Our physicians evaluate all forms of this lung condition including:

  • Acute interstitial pneumonia (AIP or Hamman-Rich syndrome)
  • Connective tissue-related lung fibrosis (scleroderma, systemic lupus erythematosis, Sjogren's, rheumatoid arthritis)
  • Drug-induced lung fibrosis
  • Hypersensitivity pneumonitis
  • Idiopathic forms of lung fibrosis
  • Langerhan's cell histiocytosis (aka Eosinophilic granuloma or Histiocytosis X)
  • Occupational-related lung fibrosis (e.g. asbestosis)
  • Pulmonary alveolar proteinosis (PAP)
  • Radiation-induced lung fibrosis
  • Sarcoidosis

Risk Factors

  • Use of specific prescription medications
  • Various environmental and occupational exposures
  • Advanced age
  • Genetics/family history
  • Autoimmune conditions
  • Smoking
  • Prior radiation or chemotherapy

Classic Symptoms

  • Shortness of breath when at rest or with movement
  • Chronic dry cough
  • Fatigue
  • Weakness
  • Decreased appetite
  • Joint Pain

Common Treatments

The primary goal in the treatment of ILD is to reduce the buildup of scar tissue. Sometimes this involves treating patients with drugs that actually restrict the cells that make scar tissue. Other times we use therapies that try to stop the primary process such as avoiding exposure to specific environmental insults or stopping the immune system from damaging the lungs.

Common therapies (medications and non-drug therapies) used to treat ILD include:

  • Prednisone
  • Mycophenolate, Cytoxan, Imuran and other immune suppressive agents
  • Anti-fibrotics such as Pirfenidone and Nintedanib
  • Oxygen Therapy
  • Pulmonary Rehab
  • Lung Transplant

Clinical Trials for Interstitial Lung Disease

Although our physicians follow evidence-based guidelines for all conditions, we also offer enrollment in clinical trials for those patients with conditions that have limited effective treatments.

This therapy aims to reduce morbidity and mortality from this serious condition.

For more information, call 215-955-5161 (select option 2) or e-mail Ross.Summer@jefferson.edu.